Nonclinical vaccine safety evaluation: Advantages of continuous temperature monitoring using abdominally implanted data loggers

Journal of Applied Toxicology

Volumn 33, Issue 6, 2013, Pages 521-526

  Kaaijk, Patricia ^a   Van Der Ark, Arno A J ^a   Van Amerongen, Geert ^b   Van Den Dobbelsteen, Germie P J M ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b NETHERLANDS VACCINE INSTITUTE   (Netherlands)

Author keywords

Body temperature; Data logger; Nonclinical; Safety; Vaccine

Indexed keywords

MENINGOCOCCUS VACCINE; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BODY TEMPERATURE MEASUREMENT; DRUG SAFETY; FEMALE; GOOD LABORATORY PRACTICE; INFORMATION PROCESSING DEVICE; NEISSERIA MENINGITIDIS; NONHUMAN; PERITONEAL CAVITY; PRIORITY JOURNAL; RECTUM TEMPERATURE; VACCINATION;

ANIMALS; ANIMALS, NEWBORN; BODY TEMPERATURE; DATA INTERPRETATION, STATISTICAL; ELECTRODES, IMPLANTED; FEMALE; FEVER; IMMUNIZATION SCHEDULE; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; PERITONEAL CAVITY; PERTUSSIS VACCINE; RABBITS; RECTUM; SAFETY; TELEMETRY; THERMOMETERS; VACCINES;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 84876708291     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.2720     Document Type: Article

References (18)

1. Biswas SK, Lopez-Collazo E. 2009. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol. 30: 475-487.
2. Brennan FR, Dougan G. 2005. Non-clinical safety evaluation of novel vaccines and adjuvants: new products, new strategies. Vaccine 23: 3210-3222.
3. Chen PH, White CE. 2006. Comparison of rectal, microchip transponder, and infrared thermometry techniques for obtaining body temperature in the laboratory rabbit (Oryctolagus cuniculus). J. Am. Assoc. Lab. Anim. Sci. 45: 57-63.
4. Galanos C, Rietschel ET. 1986. Bacterial endotoxins. Infection 14: 155.
5. Geier DA, Geier MR. 2002. Clinical implications of endotoxin concentrations in vaccines. Ann. Pharmacother. 36: 776-780.
6. Greisman SE, Hornick RB. 1969. Comparative pyrogenic reactivity of rabbit and man to bacterial endotoxin. Proc. Soc. Exp. Biol. Med. 131: 1154-1158.
7. Hartung T, Aaberge I, Berthold S, Carlin G, Charton E, Coecke S, Fennrich S, Fischer M, Gommer M, Halder M, Haslov K, Jahnke M, Montag-Lessing T, Poole S, Schechtman L, Wendel A, Werner-Felmayer G. 2001. Novel pyrogen tests based on the human fever reaction. The report and recommendations of ECVAM Workshop 43. European Centre for the Validation of Alternative Methods. European Centre for the Validation of Alternative Methods. Altern. Lab. Anim. 29: 99-123.
8. Kaaijk P, van Straaten I, Boot E, van Dijken D, van den Dobbelsteen G. 2011. Preclinical safety and immunogenicity evaluation of a new generation nonavalent PorA OMV vaccine against serogroup B meningococcus. Poster presented as part of the Meningitis Research Foundation Conference on meningitis and septicaemia in children and adults, London, 8-9 November 2011.
9. Kox M, de Kleijn S, Pompe JC, Ramakers BP, Netea MG, van der Hoeven JG, Hoedemaekers CW, Pickkers P. 2011. Differential ex vivo and in vivo endotoxin tolerance kinetics following human endotoxemia. Crit. Care Med. 39: 1866-1870.
10. Labrie JE, Keiser PB. 2010. Whole cell vaccination for meningococcus: lessons from an idea for which time has gone. Hum. Vaccines 6: 360-365.
11. Quimby JM, Olea-Popelka F, Lappin MR. 2009. Comparison of digital rectal and microchip transponder thermometry in cats. J. Am. Assoc. Lab. Anim. Sci. 48: 402-404.
12. Tapiainen T, Heininger U. 2005. Fever following immunization. Expert Rev. Vaccines 4: 419-427.
13. van der Ley P, Steeghs L, Hamstra HJ, ten Hove J, Zomer B, van Alphen L. 2001. Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity. Infect. Immun. 69: 5981-5990.
14. van de Waterbeemd B, Streefland M, van der Ley P, Zomer B, van Dijken H, Martens D, Wijffels R, van der Pol L. 2010. Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process. Vaccine 28: 4810-4816.
15. Verdier F. 2002. Non-clinical vaccine safety assessment. Toxicology 174: 37-43.
16. Verwer CM, van der Ark A, van Amerongen G, van den Bos R, Hendriksen CF. 2009. Reducing variation in a rabbit vaccine safety study with particular emphasis on housing conditions and handling. Lab. Anim. 43: 155-164.
17. Wolf JJ, Kaplanski CV, Lebron JA. 2010. Nonclinical safety assessment of vaccines and adjuvants. Meth. Mol. Biol. 626: 29-40.
18. Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, Haber P, Pless RP, Mootrey G, Ellenberg SS, Braun MM, Chen RT. 2003. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS) - United States, 1991-2001. MMWR Surveill. Summ. 52: 1-24.